Buy 3SBio Up to $10
3SBio Inc. (SSRX - Snapshot Report) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product EPIAO is the number 1 brand in China's EPO [erythropoietin] market.
Its second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deal with US-based AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report) will boost its expansion into IV Iron market.
We believe shares of 3SBio are undervalued and are attractive at current levels. We maintain a Buy rating with a price target of $10.
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Zacks FREE Registration
X Close
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 26, 2009 12:09 pm ET |
Sponsored Links


Sponsored Links 
0.44 %
-2.22 %

[CLICK TO CLOSE X]